Daniel Pichl - Feb 2, 2024 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)

Role
Chief People Officer
Signature
/s/ Francis I. Perier, Jr. as Attorney-in Fact
Stock symbol
SWTX
Transactions as of
Feb 2, 2024
Transactions value $
-$711,212
Form type
4
Date filed
2/5/2024, 09:23 PM
Previous filing
Jan 8, 2024
Next filing
Feb 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SWTX Common Stock Options Exercise $449K +16.3K +29.47% $27.64 71.4K Feb 2, 2024 Direct F1
transaction SWTX Common Stock Sale -$406K -9.27K -12.98% $43.81 62.1K Feb 2, 2024 Direct F1, F2
transaction SWTX Common Stock Sale -$628K -14.2K -22.82% $44.31 48K Feb 2, 2024 Direct F1, F3
transaction SWTX Common Stock Sale -$91.8K -2K -4.16% $45.95 46K Feb 2, 2024 Direct F1, F4
transaction SWTX Common Stock Sale -$34.5K -743 -1.62% $46.44 45.2K Feb 2, 2024 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SWTX Stock Option (Right to Buy) Options Exercise $0 -16.3K -25% $0.00 48.8K Feb 2, 2024 Common Stock 16.3K $27.64 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on March 9, 2023.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.05 to $44.045. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.05 to $44.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.29 to $46.23. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.31 to $47.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 Twenty-five percent (25%) of this option shall vest and become exercisable on January 5, 2024, with the remaining seventy-five percent (75%) to vest in thirty-six (36) equal monthly installments thereafter subject to continued service to the Issuer by the Reporting Person.